Therapy Detail

Therapy Name Paclitaxel + Doxorubicin + Cyclophosphamide
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cyclophosphamide Cytoxan CPM Chemotherapy - Alkylating 14 Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
Doxorubicin Adriamycin Adria|ADR Chemotherapy - Anthracycline 11 TOPO2 inhibitor 4 Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov).
Paclitaxel Taxol 7-Epipaclitaxel Antimicrotubule Agent 11 BCL2 Family Inhibitor 6 Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01275677 Phase III Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide Docetaxel + Cyclophosphamide Docetaxel + Cyclophosphamide + Trastuzumab Paclitaxel + Doxorubicin + Cyclophosphamide Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Active, not recruiting
NCT03725059 Phase III Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Epirubicin + Paclitaxel Pembrolizumab Paclitaxel + Doxorubicin + Cyclophosphamide Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) Recruiting
NCT03554109 Phase II NANT triple negative breast cancer vaccine combination Paclitaxel + Doxorubicin + Cyclophosphamide QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine Not yet recruiting
NCT01042379 Phase II Trebananib Pertuzumab + Trastuzumab Ganitumab Paclitaxel + Doxorubicin + Cyclophosphamide MK2206 + Trastuzumab Trebananib + Trastuzumab T-DM1 + Pertuzumab I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Recruiting
NCT02637375 Phase I Paclitaxel + Doxorubicin + Cyclophosphamide Ganetespib A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer Withdrawn
NCT02957968 Phase II Paclitaxel + Doxorubicin + Cyclophosphamide Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Recruiting
NCT02132949 Phase II Pertuzumab + Trastuzumab Paclitaxel + Doxorubicin + Cyclophosphamide Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer. Active, not recruiting
NCT02379585 Phase Ib/II Paclitaxel + Doxorubicin + Cyclophosphamide Pertuzumab + Trastuzumab + Docetaxel Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer Terminated